Vemlidy (Tenofovir Alafenamide) Patent Expiration, LOE Window & CMS Spending
Vemlidy (Tenofovir Alafenamide) by Gilead Sciences: FDA Orange Book core substance LOE 2033-02-15, 1 AB generics, $300.3M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Gilead Sciences |
| FDA Application & Pathway | N208464 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2033-02-15 |
| Last Listed Patent or Exclusivity Date | 2033-02-15 |
| Orange Book Patents (*PED Extensions) | 4 patents (2 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $300.3M |
| 2024 Medicare Part D Spend | $199.0M |
| 2024 Medicaid Spend | $101.4M |
| Reported Wholesale Price Change (CA SB 17) | 4 WAC filings (max 17.6% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.